Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | HTR1D | P28221 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828488 | 1.00 | CA2 (0.42) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5722725 | 1.00 | CA2 (0.42) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL7222682 | 1.00 | CA2 (0.42) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29462397 | 0.92 | CA2 (0.46) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1934942 | 0.82 | CA2 (0.38) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30703411 | 0.81 | CHRM2 (0.42) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1567113 | 0.80 | HTR1A (0.45) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2395914 | 0.80 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1451005 | 0.79 | STS (0.47) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL27918729 | 0.77 | CHRM2 (0.36) | CA2CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405467-B1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | MENARINI INT OPERATIONS LUXEMBOURG SA (LU) | 2021-08-04 | — | — | EP | disclosed |
| US-10392361-B2 | Process for the synthesis of intermediates of Nebivolol | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2019-08-27 | — | — | US | disclosed |
| US-20190031636-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2019-01-31 | — | — | US | disclosed |
| EP-3405467-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | Menarini International Operations Luxembourg S.A. (LU) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017125900-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2017-07-27 | — | — | WO | disclosed |
| EP-1803716-B1 | A process for preparation of racemic nebivolol | ACINO PHARMA AG (CH) | 2012-07-25 | — | — | EP | disclosed |
| US-7560575-B2 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2009-07-14 | — | — | US | disclosed |
| US-7560575-B2 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2009-07-14 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| WO-2008010022-A2 | A PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1803716-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| EP-1803715-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-6545040-B1 | Method of lowering the blood pressure | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-0184257-B1 | BENZOXAZOL- AND BENZOTHIAZOLAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-25 | — | — | EP | disclosed |
| EP-0145067-B1 | DERIVATIVES OF 2,2'-IMINOBISETHANOL | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392361-B2 | Process for the synthesis of intermediates of Nebivolol | ADRB3, ADRB2, ADRB1 | CA2 2394/4885CHRM2 249/4885CHRM4 130/4885 |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | ADRB1, ADRB2, ADRA2B | CA2 4276/4885CHRM2 128/4885CHRM4 277/4885 |
| US-20190031636-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | ADRB3, ADRB2, ADRB1 | CA2 2394/4885CHRM2 249/4885CHRM4 130/4885 |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ADRB1, ADRB2, ADRA2B | CA2 4276/4885CHRM2 128/4885CHRM4 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.